Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 15/20 | 0.61 |
| ▸ | CDK2 | P24941 | 15/20 | 0.61 |
| ▸ | CDK4 | P11802 | 14/20 | 0.61 |
| ▸ | CCND1 | P24385 | 14/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CASK | O14936 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | CDK14 | O94921 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAK | P20794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838032 | 0.91 | CDK1 (0.56) | CDK1CDK2CDK4CCND1OPRM1 | |
| SCHEMBL3835761 | 0.90 | CDK1 (0.55) | CDK1CDK2CDK4CCND1MAP4K4 | |
| SCHEMBL3841462 | 0.89 | CDK1 (0.61) | CDK1CDK2CDK4CCND1MAPK8 | |
| SCHEMBL3840949 | 0.89 | CDK1 (0.58) | CDK1CDK2CDK4CCND1OPRM1 | |
| SCHEMBL3839698 | 0.89 | CDK1 (0.58) | CDK1CDK2CDK4CCND1OPRM1 | |
| SCHEMBL3836166 | 0.89 | CDK1 (0.58) | CDK1CDK2CDK4CCND1OPRM1 | |
| SCHEMBL3836160 | 0.88 | CDK1 (0.53) | CDK1CDK2CDK4CCND1MAP4K4 | |
| SCHEMBL3835475 | 0.87 | CDK1 (0.54) | CDK1CDK2CDK4CCND1MAPK8 | |
| SCHEMBL3835597 | 0.87 | CDK1 (0.59) | CDK1CDK2CDK4CCND1CASK | |
| SCHEMBL3835498 | 0.86 | CDK1 (0.64) | CDK1CDK2CDK4CCND1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | claimed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | claimed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | claimed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | CDK1 6/4885CDK2 1/4885CDK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.